For GC-DLBCL that shows a great dependency on AKT mediated by SYK activation [95,96], HSP90 targeting seems a good option to neutralize two client proteins essential for lymphoma survival. This evidence concerns the gene HSP90AB1 and diffuse large B-cell lymphoma.